MultiValent Biotherapies is developing a peptide-like drug conjugate that hits two validated targets to treat prostate cancer ...
MultiValent Biotherapies, Inc. (MultiValent), a private biotechnology company developing targeted drug conjugate therapies for cancer, announced a $27.425 million first closing of its Series A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results